title: Haematological cancer: Idelalisib for CLL - risky benefit.
authors.forename: Diana
authors.initials: D
authors.lastname: Romero
mesh_terms: D000970:Antineoplastic Agents; D019337:Hematologic Neoplasms; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell; D011687:Purines; D052999:Quinazolinones
chemical_list: D000970:Antineoplastic Agents; D011687:Purines; D052999:Quinazolinones; C552946:idelalisib